OBJECTIVES: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of drugs used to treat type 2 diabetes (T2D).  In this study, we developed a model to estimate the societal cost of the following GLP-1RAs currently on the market: exenatide QW, liraglutide 1.2/1.8 mg, albiglutide, and dulaglutide.  METHODS: We developed a decision analytic model to estimate the total societal cost of exenatide QW, liraglutide 1.2/1.8mg, albiglutide, and dulaglutide as strategies for the management of T2D. For each treatment strategy, patients either reached A1C goal (<7%) or did not. Additional direct and indirect medical costs were associated with not reaching goal. Direct costs included pharmacy costs and medical costs. Indirect costs included absenteeism, presenteeism, and mortality (based on the value of a statistical life [VSL] assigned to patients who died). Clinical inputs were sourced from a recent meta-analysis of GLP-1RA treatments. Cost data were taken from a review of the literature. All costs were adjusted to 2015 USD.  RESULTS: Ordered from lowest to highest, total costs associated with each strategy were $95,996 (direct: $6,774; indirect: $89,222) for exenatide QW, $96,545 (direct: $7,078; indirect: $89,467) for dulaglutide, $96,614 (direct: $7,095; indirect: $89,519) for liraglutide, and $101,169 (direct: $5,476; indirect: $95,693) for albiglutide. For each of the strategies, the most influential parameters were VSL, background mortality rate, mortality hazard ratio (HR) for not reaching goal, and effectiveness (% of patients reaching A1C goal). CONCLUSIONS: Understanding the total societal value of a treatment will be important when choosing a medication for the treatment of T2D. While the trial results and direct costs between GLP-1RAs were similar, treatment with exenatide QW resulted in the lowest estimated total costs to society. Long-term follow-up data on mortality following failure to reach goal are needed to assess the validity of these projections.